Cardiac amyloidosis is an often overlooked and thus misdiagnosed form of a restrictive cardiomyopathy in which delayed diagnosis is associated with significant morbidity and mortality. Immunoglobulin light chain (AL) cardiac amyloidosis is the most deadly from of cardiac amyloidosis but significant progress has been made in treatment with the first FDA approved therapy for this condition - daratumumab.

In this interview, Mathew Maurer, MD and Stephen J. Nicholls, MBBS, PhD, FACC, with Yuvraj Chowdhury, MD, discuss Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis--Focus on AL.